Emerging therapies in cancer metabolism

Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and...

Full description

Saved in:
Bibliographic Details
Published inCell metabolism Vol. 35; no. 8; pp. 1283 - 1303
Main Authors Xiao, Yi, Yu, Tian-Jian, Xu, Ying, Ding, Rui, Wang, Yi-Ping, Jiang, Yi-Zhou, Shao, Zhi-Ming
Format Journal Article
LanguageEnglish
Published United States 08.08.2023
Subjects
Humans
Metabolic Networks and Pathways
Neoplasms - metabolism
Online AccessGet full text

Cover

Abstract Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and adaptability of metabolic networks hinder the effectiveness of metabolic therapies. This review summarizes the metabolic targets for cancer treatment and provides an overview of the current status of clinical trials targeting cancer metabolism. Additionally, we decipher crucial factors that limit the efficacy of metabolism-based therapies and propose future directions. With advances in integrating multi-omics, single-cell, and spatial technologies, as well as the ability to track metabolic adaptation more precisely and dynamically, clinicians can personalize metabolic therapies for improved cancer treatment.
AbstractList Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and adaptability of metabolic networks hinder the effectiveness of metabolic therapies. This review summarizes the metabolic targets for cancer treatment and provides an overview of the current status of clinical trials targeting cancer metabolism. Additionally, we decipher crucial factors that limit the efficacy of metabolism-based therapies and propose future directions. With advances in integrating multi-omics, single-cell, and spatial technologies, as well as the ability to track metabolic adaptation more precisely and dynamically, clinicians can personalize metabolic therapies for improved cancer treatment.
Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and adaptability of metabolic networks hinder the effectiveness of metabolic therapies. This review summarizes the metabolic targets for cancer treatment and provides an overview of the current status of clinical trials targeting cancer metabolism. Additionally, we decipher crucial factors that limit the efficacy of metabolism-based therapies and propose future directions. With advances in integrating multi-omics, single-cell, and spatial technologies, as well as the ability to track metabolic adaptation more precisely and dynamically, clinicians can personalize metabolic therapies for improved cancer treatment.Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and adaptability of metabolic networks hinder the effectiveness of metabolic therapies. This review summarizes the metabolic targets for cancer treatment and provides an overview of the current status of clinical trials targeting cancer metabolism. Additionally, we decipher crucial factors that limit the efficacy of metabolism-based therapies and propose future directions. With advances in integrating multi-omics, single-cell, and spatial technologies, as well as the ability to track metabolic adaptation more precisely and dynamically, clinicians can personalize metabolic therapies for improved cancer treatment.
Author Wang, Yi-Ping
Ding, Rui
Xu, Ying
Shao, Zhi-Ming
Jiang, Yi-Zhou
Yu, Tian-Jian
Xiao, Yi
Author_xml – sequence: 1
  givenname: Yi
  surname: Xiao
  fullname: Xiao, Yi
– sequence: 2
  givenname: Tian-Jian
  surname: Yu
  fullname: Yu, Tian-Jian
– sequence: 3
  givenname: Ying
  surname: Xu
  fullname: Xu, Ying
– sequence: 4
  givenname: Rui
  surname: Ding
  fullname: Ding, Rui
– sequence: 5
  givenname: Yi-Ping
  surname: Wang
  fullname: Wang, Yi-Ping
– sequence: 6
  givenname: Yi-Zhou
  surname: Jiang
  fullname: Jiang, Yi-Zhou
– sequence: 7
  givenname: Zhi-Ming
  surname: Shao
  fullname: Shao, Zhi-Ming
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37557070$$D View this record in MEDLINE/PubMed
BookMark eNp9kElPwzAQhS1URBf4AxxQbnBJGC-xkyOqyiJV4gJny3EmxVWWYqcH_j2u2l44oJFmrNF7b-RvTib90CMhtxQyClQ-bjPb4ZgxYDwDlQHICzKjJWepEgwm8Z3nkArK6ZTMQ9gCcMlLfkWmXOW5AgUzcr_q0G9cv0nGL_Rm5zAkrk-s6S36JMabamhd6K7JZWPagDenuSCfz6uP5Wu6fn95Wz6tU8uFGtPKWFbLCmUJuZGiqIumQFMCRyNqYYWysQmUGM9LJpBKxuIWmqq0zCLlC_JwzN354XuPYdSdCxbb1vQ47INmhSgKwWJF6d1Juq86rPXOu874H33-XBQUR4H1QwgeG23daEY39KM3rtUU9IGj3uoDR33gqEHpyDFa2R_rOf0f0y9AjnYP
CitedBy_id crossref_primary_10_3389_fphar_2024_1442888
crossref_primary_10_1016_j_biomaterials_2024_123022
crossref_primary_10_1038_s41392_024_02104_8
crossref_primary_10_1016_j_intimp_2024_113412
crossref_primary_10_1016_j_xcrm_2024_101580
crossref_primary_10_1186_s13046_024_03094_9
crossref_primary_10_1007_s12672_025_02083_4
crossref_primary_10_1016_j_jare_2024_11_021
crossref_primary_10_1186_s12929_024_01013_w
crossref_primary_10_1186_s40364_024_00646_1
crossref_primary_10_3389_fimmu_2024_1517679
crossref_primary_10_3892_or_2024_8714
crossref_primary_10_1016_j_cmet_2024_05_013
crossref_primary_10_1016_j_apsb_2024_07_005
crossref_primary_10_3390_cancers16030624
crossref_primary_10_1186_s12967_025_06086_1
crossref_primary_10_1016_j_neo_2024_101076
crossref_primary_10_3390_cells14060402
crossref_primary_10_1073_pnas_2319429121
crossref_primary_10_1002_ctm2_70145
crossref_primary_10_1016_j_eng_2024_11_036
crossref_primary_10_1158_2159_8290_CD_23_1509
crossref_primary_10_3390_metabo15030201
crossref_primary_10_1038_s41419_024_06930_0
crossref_primary_10_15430_JCP_24_002
crossref_primary_10_1111_jgh_16879
crossref_primary_10_3389_fonc_2024_1413213
crossref_primary_10_1016_j_canlet_2024_217091
crossref_primary_10_3390_ijms26051879
crossref_primary_10_1016_j_apsb_2024_07_015
crossref_primary_10_1039_D4TB00769G
crossref_primary_10_1186_s10020_024_00988_4
crossref_primary_10_1038_s41392_024_02120_8
crossref_primary_10_1002_ctm2_70215
crossref_primary_10_3389_fphar_2024_1423629
crossref_primary_10_1016_j_isci_2024_110710
crossref_primary_10_1186_s12967_024_05545_5
crossref_primary_10_1002_wnan_2010
crossref_primary_10_1158_0008_5472_CAN_23_3594
crossref_primary_10_1080_14737140_2024_2372336
crossref_primary_10_1177_15330338241282080
crossref_primary_10_1007_s10495_024_02032_6
crossref_primary_10_1016_j_colsurfb_2024_114162
crossref_primary_10_1039_D4CS00404C
crossref_primary_10_3390_ijms26031186
crossref_primary_10_1016_j_canlet_2025_217512
crossref_primary_10_3389_fimmu_2024_1275203
crossref_primary_10_1016_j_nbd_2024_106541
crossref_primary_10_1016_j_ejphar_2024_176912
crossref_primary_10_1016_j_colsurfb_2024_114398
crossref_primary_10_1186_s12967_023_04804_1
crossref_primary_10_1172_JCI177606
crossref_primary_10_1016_j_tifs_2023_104192
crossref_primary_10_3389_fcell_2025_1535073
crossref_primary_10_3390_antiox13070828
crossref_primary_10_1016_j_cej_2024_149248
crossref_primary_10_3389_fimmu_2024_1462174
crossref_primary_10_1016_j_actbio_2025_02_008
crossref_primary_10_1038_s41568_024_00679_6
crossref_primary_10_1016_j_trecan_2023_10_002
crossref_primary_10_1186_s12943_024_02119_3
crossref_primary_10_32604_biocell_2023_030781
crossref_primary_10_1002_advs_202409967
crossref_primary_10_1002_advs_202409329
crossref_primary_10_1093_nar_gkae954
crossref_primary_10_3390_ijms242115787
crossref_primary_10_3389_fbioe_2024_1383930
crossref_primary_10_1016_j_molmed_2025_01_016
crossref_primary_10_1016_j_bbadis_2024_167248
crossref_primary_10_1016_j_drudis_2024_104220
crossref_primary_10_1016_j_intimp_2025_114376
crossref_primary_10_1038_s41368_024_00310_2
crossref_primary_10_1016_j_tem_2024_02_008
crossref_primary_10_7717_peerj_19083
crossref_primary_10_1016_j_devcel_2024_12_035
crossref_primary_10_3390_pharmaceutics16081028
crossref_primary_10_1016_j_molmet_2025_102113
crossref_primary_10_1038_s42003_024_07209_y
crossref_primary_10_1016_j_jhepr_2024_101009
crossref_primary_10_32604_biocell_2024_056374
crossref_primary_10_3390_cancers16203513
crossref_primary_10_1016_j_drup_2025_101215
Cites_doi 10.1016/j.cell.2022.06.029
10.1093/annonc/mdw410
10.1016/j.ijrobp.2020.06.021
10.1186/s12918-017-0464-7
10.1001/jama.2022.6147
10.1038/s41568-022-00485-y
10.1016/j.ijbiomac.2022.07.123
10.1016/j.cell.2012.03.042
10.1038/s41556-022-01002-x
10.1016/S1470-2045(20)30157-1
10.1158/2159-8290.CD-21-1059
10.1001/jamaoncol.2022.3511
10.1016/j.cmet.2023.01.012
10.1016/j.immuni.2022.01.006
10.7554/eLife.59996
10.1038/onc.2016.370
10.1016/j.celrep.2019.07.027
10.1016/j.drup.2021.100797
10.1073/pnas.1807305115
10.1111/jnc.14250
10.1038/s41586-022-05661-6
10.1016/j.ccell.2020.04.005
10.1084/jem.118.1.99
10.1016/j.cllc.2020.07.012
10.1016/j.ccell.2022.01.001
10.1038/s41591-019-0458-7
10.2174/1875044301205010047
10.1016/j.immuni.2015.02.005
10.1158/0008-5472.CAN-21-0747
10.1172/JCI131859
10.1038/s41586-020-2502-7
10.1038/s41568-022-00459-0
10.1016/j.ccell.2023.01.009
10.1038/s41467-022-28452-z
10.4103/0976-500X.184769
10.1172/jci.insight.145207
10.1038/s42255-019-0043-x
10.1126/scitranslmed.abj5070
10.1038/nature22056
10.1158/2159-8290.CD-20-0844
10.1182/blood.V99.6.1986
10.1016/j.cmet.2019.08.013
10.1158/1535-7163.MCT-20-0567
10.1038/s41416-019-0664-6
10.1038/s41416-020-0827-5
10.1074/mcp.RA119.001576
10.1038/nature17412
10.1200/JCO.2021.39.15_suppl.3001
10.1038/s41573-021-00339-6
10.3390/ijms19123871
10.1002/cmdc.201600276
10.1158/0008-5472.CAN-21-2745
10.1016/j.cmet.2022.08.016
10.1080/09637486.2020.1746959
10.1038/s41467-022-32521-8
10.1016/j.redox.2021.102076
10.1016/j.ccell.2022.05.009
10.3389/fped.2022.902117
10.1200/JCO.2017.35.15_suppl.3003
10.1038/s41568-021-00435-0
10.1158/2326-6066.CIR-20-0586
10.7554/eLife.02242
10.1007/s00520-020-05879-y
10.1053/j.gastro.2018.05.024
10.3389/fonc.2019.01201
10.1016/j.trecan.2022.12.006
10.1200/JCO.2023.41.6_suppl.173
10.1002/cncr.34512
10.1158/1078-0432.CCR-21-4383
10.1016/j.cell.2020.10.016
10.1126/science.aaw5473
10.1158/1535-7163.MCT-20-0550
10.1038/s43018-021-00183-y
10.1038/s41586-019-1437-3
10.1016/j.ccell.2022.05.006
10.1016/S0959-8049(98)00058-6
10.1038/s42255-020-0174-0
10.1016/j.cmet.2021.04.003
10.1038/s41419-020-02768-4
10.1016/j.cell.2023.01.038
10.1016/j.trecan.2021.02.004
10.1182/blood.2021014901
10.2217/fon-2019-0209
10.1158/0008-5472.CAN-09-3871
10.1016/j.cmet.2020.10.012
10.1056/NEJM198609113151101
10.1016/j.cmet.2022.06.010
10.1016/j.trecan.2021.04.003
10.1016/j.cmet.2022.02.010
10.1016/j.cmet.2021.12.001
10.1007/BF01119794
10.1038/nrc1074
10.1126/scitranslmed.3003293
10.1016/j.cmet.2023.02.013
10.1073/pnas.1808834116
10.1038/s41568-022-00473-2
10.1038/s41573-019-0016-5
10.1016/j.cmet.2022.01.007
10.1038/s41586-020-2363-0
10.1158/1078-0432.CCR-22-0061
10.1016/j.cmet.2017.11.001
10.3389/fphar.2022.970553
10.3390/biom12060815
10.1016/j.cell.2016.09.031
10.1038/s43018-020-0035-5
10.1016/j.ccell.2022.12.008
10.1016/j.ccell.2022.07.012
10.1007/s10549-019-05146-7
10.1038/nature07782
10.1016/j.drup.2019.100670
10.3389/fphar.2020.00656
10.1200/JCO.2016.72.0326
10.1016/j.ctrv.2021.102334
10.1007/s00109-020-01959-y
10.1158/0008-5472.CAN-20-1628
10.1001/jamaoncol.2021.3836
10.1002/advs.202100311
10.1038/s41556-019-0299-0
10.1016/j.jshs.2020.07.008
10.1016/j.neo.2020.12.009
10.1038/s41586-022-05443-0
10.1038/s41591-022-02103-8
10.1056/NEJM194806032382301
10.1038/s41586-022-04758-2
10.1038/s42255-022-00582-0
10.1016/j.molcel.2021.03.037
10.1038/s41556-021-00820-9
10.1016/j.cmet.2019.01.011
10.1126/science.124.3215.269
10.1021/acs.jmedchem.9b00718
10.1016/j.ccell.2015.12.004
10.7554/eLife.61980
10.1200/JCO.2018.78.9602
10.1038/s41418-019-0352-3
10.1126/science.ade3332
10.1016/j.molcel.2022.03.022
10.1038/s41568-023-00557-7
10.1016/j.copbio.2022.102693
10.1016/j.cmet.2019.02.001
10.1038/s41586-022-04649-6
10.1016/S1470-2045(19)30274-8
10.1038/s41392-020-00326-0
10.1084/jem.98.6.565
10.1200/JCO.22.00687
10.1158/2159-8290.CD-22-0244
10.1038/nbt.1614
10.1016/j.phrs.2019.104511
10.1038/s41568-020-0273-y
10.1016/j.ccell.2017.02.018
10.1038/s41467-020-17512-x
10.1016/j.cell.2021.09.020
10.1038/s41573-022-00493-5
10.1038/s41467-020-18020-8
10.1016/j.cmet.2017.09.018
10.1089/ars.2017.7485
10.1038/nchem.2778
10.1038/s41568-018-0061-0
10.1158/1078-0432.CCR-17-2575
10.1016/j.cmet.2021.01.018
10.1016/j.immuni.2022.07.017
10.1007/s13238-017-0451-1
10.1186/s12943-021-01316-8
10.1038/bjc.2016.152
10.1038/nature11743
10.1016/j.ccell.2022.07.011
10.1056/NEJMc1105726
10.1016/j.cmet.2023.01.010
10.1126/scitranslmed.abc8188
10.1016/j.cmet.2018.09.002
10.1016/j.cmet.2020.11.007
10.1126/scitranslmed.abk2756
10.1016/j.immuni.2019.12.011
10.1038/s41580-019-0108-4
10.4103/0973-1482.55136
10.1371/journal.pone.0127246
10.1016/j.ccell.2018.04.011
10.1038/s41591-019-0404-8
10.1038/s41586-021-03442-1
10.1038/s41568-021-00388-4
10.1056/NEJMoa1716984
10.1158/2159-8290.CD-20-1680
10.1016/j.cmet.2020.10.021
10.1016/j.pharmthera.2015.02.004
10.1158/1078-0432.CCR-17-3070
10.1038/s41467-021-26431-4
10.1158/2159-8290.CD-21-0218
10.1182/blood-2014-12-617498
10.1016/j.cmet.2021.03.009
10.1038/s42255-022-00636-3
10.1073/pnas.1808950116
10.1016/j.cmet.2022.11.011
10.1038/s41586-018-0343-4
10.1111/obr.13358
10.1016/S2352-3026(22)00292-7
10.1016/j.cmet.2017.09.006
10.1038/s41392-021-00831-w
10.18632/oncotarget.17396
10.1016/j.cell.2018.03.055
10.1002/msb.145122
10.1016/j.ccell.2022.02.003
10.1016/j.cmet.2022.09.021
10.1158/1538-7445.SABCS18-P6-20-07
10.1038/s41422-022-00614-0
10.1038/s41592-021-01197-1
10.1126/science.aaz6465
10.1158/2159-8290.CD-20-1227
10.1186/s13046-019-1391-9
10.1038/nrc3038
10.1038/s41586-021-04049-2
ContentType Journal Article
Copyright Copyright © 2023 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2023 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.cmet.2023.07.006
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1932-7420
EndPage 1303
ExternalDocumentID 37557070
10_1016_j_cmet_2023_07_006
Genre Journal Article
Review
GroupedDBID ---
--K
0R~
1~5
29B
2WC
4.4
457
4G.
53G
5GY
62-
6J9
7-5
AAEDT
AAEDW
AAIKJ
AAKRW
AAKUH
AALRI
AAMRU
AAVLU
AAXUO
AAYWO
AAYXX
ABDGV
ABJNI
ABMAC
ACGFO
ACGFS
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEFWE
AENEX
AEUPX
AEXQZ
AFPUW
AFTJW
AGCQF
AGHFR
AGKMS
AIGII
AITUG
AKAPO
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FCP
FDB
FEDTE
FIRID
HVGLF
HZ~
IHE
IXB
J1W
JIG
M3Z
M41
O-L
O9-
OK1
OZT
P2P
RIG
ROL
RPZ
SES
SSZ
TR2
UNMZH
AACTN
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFKBS
ID FETCH-LOGICAL-c347t-bac2d6be6905a648d8f8ea903ea4d4c47c4c44e6e570624e1622c470fb9c2ce13
ISSN 1550-4131
1932-7420
IngestDate Mon Jul 21 09:42:25 EDT 2025
Thu Apr 03 07:01:22 EDT 2025
Tue Jul 01 03:58:21 EDT 2025
Thu Apr 24 22:58:19 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License Copyright © 2023 Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c347t-bac2d6be6905a648d8f8ea903ea4d4c47c4c44e6e570624e1622c470fb9c2ce13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://www.cell.com/article/S1550413123002656/pdf
PMID 37557070
PQID 2848842424
PQPubID 23479
PageCount 21
ParticipantIDs proquest_miscellaneous_2848842424
pubmed_primary_37557070
crossref_citationtrail_10_1016_j_cmet_2023_07_006
crossref_primary_10_1016_j_cmet_2023_07_006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-08-08
PublicationDateYYYYMMDD 2023-08-08
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-08
  day: 08
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cell metabolism
PublicationTitleAlternate Cell Metab
PublicationYear 2023
References Lu (10.1016/j.cmet.2023.07.006_bib110) 2017; 8
Weiss-Sadan (10.1016/j.cmet.2023.07.006_bib44) 2023; 35
DeBerardinis (10.1016/j.cmet.2023.07.006_bib209) 2022; 185
Tannir (10.1016/j.cmet.2023.07.006_bib140) 2022; 8
Finley (10.1016/j.cmet.2023.07.006_bib11) 2023; 186
Gao (10.1016/j.cmet.2023.07.006_bib33) 2020; 122
Lee (10.1016/j.cmet.2023.07.006_bib57) 2018; 155
Bidkhori (10.1016/j.cmet.2023.07.006_bib202) 2018; 115
Lucena-Cacace (10.1016/j.cmet.2023.07.006_bib58) 2018; 24
Pomatto-Watson (10.1016/j.cmet.2023.07.006_bib88) 2021; 12
Voss (10.1016/j.cmet.2023.07.006_bib165) 2020; 108
McDonald (10.1016/j.cmet.2023.07.006_bib22) 2020; 19
Huang (10.1016/j.cmet.2023.07.006_bib212) 2022; 119
Yap (10.1016/j.cmet.2023.07.006_bib40) 2023; 29
Barone (10.1016/j.cmet.2023.07.006_bib135) 2022; 23
Cheung (10.1016/j.cmet.2023.07.006_bib43) 2022; 22
Kim (10.1016/j.cmet.2023.07.006_bib5) 2019; 30
Abdel-Wahab (10.1016/j.cmet.2023.07.006_bib28) 2019; 150
Rossi (10.1016/j.cmet.2023.07.006_bib189) 2022; 605
Chen (10.1016/j.cmet.2023.07.006_bib177) 2022; 216
Huang (10.1016/j.cmet.2023.07.006_bib124) 2022; 24
Zhu (10.1016/j.cmet.2023.07.006_bib122) 2018; 144
Liu (10.1016/j.cmet.2023.07.006_bib109) 2019; 18
Maguire (10.1016/j.cmet.2023.07.006_bib82) 2021; 33
(10.1016/j.cmet.2023.07.006_bib147) 2001
Watts (10.1016/j.cmet.2023.07.006_bib153) 2023; 10
Zadra (10.1016/j.cmet.2023.07.006_bib118) 2019; 116
Tajan (10.1016/j.cmet.2023.07.006_bib100) 2020; 37
Gonçalves (10.1016/j.cmet.2023.07.006_bib107) 2021; 59
Chen (10.1016/j.cmet.2023.07.006_bib48) 2020; 27
Yamasaki (10.1016/j.cmet.2023.07.006_bib52) 2011; 365
Landau (10.1016/j.cmet.2023.07.006_bib10) 1958; 21
Zhang (10.1016/j.cmet.2023.07.006_bib204) 2023; 35
Mai (10.1016/j.cmet.2023.07.006_bib49) 2017; 9
Liu (10.1016/j.cmet.2023.07.006_bib208) 2023; 10
Wang (10.1016/j.cmet.2023.07.006_bib80) 2022; 55
Farber (10.1016/j.cmet.2023.07.006_bib7) 1948; 238
Lee (10.1016/j.cmet.2023.07.006_bib139) 2022; 28
Yachida (10.1016/j.cmet.2023.07.006_bib197) 2019; 25
Sun (10.1016/j.cmet.2023.07.006_bib185) 2019; 116
Sofi (10.1016/j.cmet.2023.07.006_bib90) 2020; 71
Mullen (10.1016/j.cmet.2023.07.006_bib14) 2023; 23
Wheaton (10.1016/j.cmet.2023.07.006_bib41) 2014; 3
Longley (10.1016/j.cmet.2023.07.006_bib17) 2003; 3
Weinstabl (10.1016/j.cmet.2023.07.006_bib62) 2019; 62
Halbrook (10.1016/j.cmet.2023.07.006_bib131) 2019; 29
Chen (10.1016/j.cmet.2023.07.006_bib111) 2019; 21
Tran (10.1016/j.cmet.2023.07.006_bib27) 2020; 1
Rinschen (10.1016/j.cmet.2023.07.006_bib214) 2019; 20
Hsieh (10.1016/j.cmet.2023.07.006_bib95) 2019; 28
Sampath (10.1016/j.cmet.2023.07.006_bib55) 2015; 151
Shi (10.1016/j.cmet.2023.07.006_bib23) 2022; 40
Schneider (10.1016/j.cmet.2023.07.006_bib136) 2021; 13
Nava Lauson (10.1016/j.cmet.2023.07.006_bib74) 2023; 35
(10.1016/j.cmet.2023.07.006_bib148) 2003
Kopecka (10.1016/j.cmet.2023.07.006_bib114) 2020; 49
Yu (10.1016/j.cmet.2023.07.006_bib129) 2017; 36
Egler (10.1016/j.cmet.2023.07.006_bib168) 2016; 7
Philip (10.1016/j.cmet.2023.07.006_bib146) 2019; 15
Hall (10.1016/j.cmet.2023.07.006_bib159) 2020; 21
Stine (10.1016/j.cmet.2023.07.006_bib8) 2022; 21
Kalaany (10.1016/j.cmet.2023.07.006_bib89) 2009; 458
Dai (10.1016/j.cmet.2023.07.006_bib98) 2021; 81
Sun (10.1016/j.cmet.2023.07.006_bib15) 2017; 11
Morad (10.1016/j.cmet.2023.07.006_bib193) 2021; 184
Long (10.1016/j.cmet.2023.07.006_bib158) 2019; 20
Goodwin (10.1016/j.cmet.2023.07.006_bib144) 2022; 327
Lang (10.1016/j.cmet.2023.07.006_bib50) 2019; 13
Avramis (10.1016/j.cmet.2023.07.006_bib156) 2002; 99
Liang (10.1016/j.cmet.2023.07.006_bib46) 2022; 82
Wu (10.1016/j.cmet.2023.07.006_bib29) 2020; 11
(10.1016/j.cmet.2023.07.006_bib160) 2019
de Botton (10.1016/j.cmet.2023.07.006_bib154) 2023; 141
Jha (10.1016/j.cmet.2023.07.006_bib77) 2015; 42
Lien (10.1016/j.cmet.2023.07.006_bib87) 2021; 599
Arguello (10.1016/j.cmet.2023.07.006_bib207) 2020; 32
Hertel (10.1016/j.cmet.2023.07.006_bib19) 1990; 50
Xia (10.1016/j.cmet.2023.07.006_bib76) 2021; 20
Siebeneicher (10.1016/j.cmet.2023.07.006_bib176) 2016; 11
Anderson (10.1016/j.cmet.2023.07.006_bib36) 2018; 9
Maese (10.1016/j.cmet.2023.07.006_bib61) 2022; 10
Zarei (10.1016/j.cmet.2023.07.006_bib37) 2022; 103
Sandoval-Acuña (10.1016/j.cmet.2023.07.006_bib51) 2021; 81
Bartman (10.1016/j.cmet.2023.07.006_bib217) 2023; 614
Huff (10.1016/j.cmet.2023.07.006_bib20) 2022; 12
Maddocks (10.1016/j.cmet.2023.07.006_bib102) 2013; 493
Wen (10.1016/j.cmet.2023.07.006_bib31) 2019; 38
Sahu (10.1016/j.cmet.2023.07.006_bib128) 2023; 13
Sharma (10.1016/j.cmet.2023.07.006_bib192) 2021; 11
Chen (10.1016/j.cmet.2023.07.006_bib53) 2019; 1
Sulkowski (10.1016/j.cmet.2023.07.006_bib126) 2020; 582
Reinfeld (10.1016/j.cmet.2023.07.006_bib178) 2021; 593
Karasarides (10.1016/j.cmet.2023.07.006_bib194) 2022; 10
Xiao (10.1016/j.cmet.2023.07.006_bib69) 2022; 32
Pareek (10.1016/j.cmet.2023.07.006_bib215) 2020; 368
Chen (10.1016/j.cmet.2023.07.006_bib78) 2022; 34
Fendt (10.1016/j.cmet.2023.07.006_bib187) 2020; 10
Hopkins (10.1016/j.cmet.2023.07.006_bib96) 2018; 560
Gong (10.1016/j.cmet.2023.07.006_bib180) 2021; 33
Faubert (10.1016/j.cmet.2023.07.006_bib6) 2020; 368
Achreja (10.1016/j.cmet.2023.07.006_bib199) 2022; 4
Opitz (10.1016/j.cmet.2023.07.006_bib170) 2020; 122
Ju (10.1016/j.cmet.2023.07.006_bib54) 2020; 5
Strekalova (10.1016/j.cmet.2023.07.006_bib123) 2019; 175
Ligibel (10.1016/j.cmet.2023.07.006_bib84) 2022; 40
Ravi (10.1016/j.cmet.2023.07.006_bib184) 2022; 40
Agren (10.1016/j.cmet.2023.07.006_bib203) 2014; 10
Wang (10.1016/j.cmet.2023.07.006_bib196) 2022; 34
Geiger (10.1016/j.cmet.2023.07.006_bib72) 2016; 167
Chen (10.1016/j.cmet.2023.07.006_bib181) 2021; 8
Rysman (10.1016/j.cmet.2023.07.006_bib113) 2010; 70
Rundqvist (10.1016/j.cmet.2023.07.006_bib104) 2020; 9
Zhu (10.1016/j.cmet.2023.07.006_bib152) 2021; 7
Alseekh (10.1016/j.cmet.2023.07.006_bib211) 2021; 18
Wei (10.1016/j.cmet.2023.07.006_bib56) 2022; 13
Alonso Gordoa (10.1016/j.cmet.2023.07.006_bib161) 2023; 41
Saulnier Sholler (10.1016/j.cmet.2023.07.006_bib162) 2015; 10
Yang (10.1016/j.cmet.2023.07.006_bib219) 2023; 35
Platten (10.1016/j.cmet.2023.07.006_bib64) 2019; 18
Sancho (10.1016/j.cmet.2023.07.006_bib26) 2016; 114
Arner (10.1016/j.cmet.2023.07.006_bib71) 2023; 41
Naing (10.1016/j.cmet.2023.07.006_bib172) 2023; 129
Yu (10.1016/j.cmet.2023.07.006_bib67) 2021; 81
Bridges (10.1016/j.cmet.2023.07.006_bib42) 2023; 379
Zhu (10.1016/j.cmet.2023.07.006_bib94) 2022; 7
Hoy (10.1016/j.cmet.2023.07.006_bib112) 2021; 21
Coyle (10.1016/j.cmet.2023.07.006_bib145) 2016; 27
Mitchell (10.1016/j.cmet.2023.07.006_bib157) 2018; 36
Lei (10.1016/j.cmet.2023.07.006_bib45) 2022; 22
Taylor (10.1016/j.cmet.2023.07.006_bib13) 2022; 22
Li (10.1016/j.cmet.2023.07.006_bib198) 2019; 25
Lin (10.1016/j.cmet.2023.07.006_bib125) 2019; 29
Chlebowski (10.1016/j.cmet.2023.07.006_bib164) 2017; 35
Ferrere (10.1016/j.cmet.2023.07.006_bib99) 2021; 6
Kay (10.1016/j.cmet.2023.07.006_bib81) 2022; 4
Kim (10.1016/j.cmet.2023.07.006_bib175) 2022; 612
Pavlova (10.1016/j.cmet.2023.07.006_bib4) 2022; 34
Zhang (10.1016/j.cmet.2023.07.006_bib66) 2021; 33
Koppenol (10.1016/j.cmet.2023.07.006_bib2) 2011; 11
Galli (10.1016/j.cmet.2023.07.006_bib174) 2020; 11
Parida (10.1016/j.cmet.2023.07.006_bib221) 2022; 34
Lanekoff (10.1016/j.cmet.2023.07.006_bib206) 2022; 75
Marcucci (10.1016/j.cmet.2023.07.006_bib108) 2021; 23
Oh (10.1016/j.cmet.2023.07.006_bib132) 2020; 130
Yang (10.1016/j.cmet.2023.07.006_bib73) 2016; 531
Ibrahim (10.1016/j.cmet.2023.07.006_bib86) 2021; 29
Zhou (10.1016/j.cmet.2023.07.006_bib120) 2020; 11
Andreucci (10.1016/j.cmet.2023.07.006_bib134) 2020; 98
Yap (10.1016/j.cmet.2023.07.006_bib142) 2021; 39
Wang (10.1016/j.cmet.2023.07.006_bib213) 2022; 14
Waitkus (10.1016/j.cmet.2023.07.006_bib38) 2018; 34
Dwarakanath (10.1016/j.cmet.2023.07.006_bib9) 2009; 5
Wang (10.1016/j.cmet.2023.07.006_bib116) 2018; 27
Chaiswing (10.1016/j.cmet.2023.07.006_bib121) 2018; 29
Vidal (10.1016/j.cmet.2023.07.006_bib141) 2019; 79
DiNardo (10.1016/j.cmet.2023.07.006_bib150) 2018; 378
Abou-Alfa (10.1016/j.cmet.2023.07.006_bib151) 2020; 21
Jin (10.1016/j.cmet.2023.07.006_bib21) 2021; 20
Broome (10.1016/j.cmet.2023.07.006_bib167) 1963; 118
Lee (10.1016/j.cmet.2023.07.006_bib92) 2012; 4
Elion (10.1016/j.cmet.2023.07.006_bib16) 1989; 9
Ferraro (10.1016/j.cmet.2023.07.006_bib34) 2021; 2
Kim (10.1016/j.cmet.2023.07.006_bib195) 2022; 21
Blaževitš (10.1016/j.cmet.2023.07.006_bib137) 2023; 9
Wang (10.1016/j.cmet.2023.07.006_bib85) 2021; 10
Kumagai (10.1016/j.cmet.2023.07.006_bib75) 2022; 40
Liao (10.1016/j.cmet.2023.07.006_bib179) 2022; 40
Maddocks (10.1016/j.cmet.2023.07.006_bib103) 2017; 544
Missiaen (10.1016/j.cmet.2023.07.006_bib190) 2022; 34
Jang (10.1016/j.cmet.2023.07.006_bib210) 2018; 173
Bernardes (10.1016/j.cmet.2023.07.006_bib115) 2018; 19
Rao (10.1016/j.cmet.2023.07.006_bib173) 2012; 5
Ghergurovich (10.1016/j.cmet.2023.07.006_bib218) 2021; 2
Pranzini (10.1016/j.cmet.2023.07.006_bib119) 2021; 7
Huang (10.1016/j.cmet.2023.07.006_bib63) 2020; 2
Hanahan (10.1016/j.cmet.2023.07.006_bib1) 2022; 12
Orth (10.1016/j.cmet.2023.07.006_bib201) 2010; 28
Caffa (10.1016/j.cmet.2023.07.006_bib91) 2020; 583
Dmitrieva-Posocco (10.1016/j.cmet.2023.07.006_bib97) 2022; 605
Li (10.1016/j.cmet.2023.07.006_bib222) 2023; 41
Hegde (10.1016/j.cmet.2023.07.006_bib191) 2020; 52
Yang (10.1016/j.cmet.2023.07.006_bib35) 2021; 7
Kurz (10.1016/j.cmet.2023.07.006_bib106) 2022; 40
Leone (10.1016/j.cmet.2023.07.006_bib70) 2020; 20
Egan (10.1016/j.cmet.2023.07.006_bib25) 2021; 11
Banh (10.1016/j.cmet.2023.07.006_bib83) 2020; 183
Thomas (10.1016/j.cmet.2023.07.006_bib200) 2023; 13
Han (10.1016/j.cmet.2023.07.006_bib117) 2019; 9
Chen (10.1016/j.cmet.2023.07.006_bib68) 2022; 13
Wang (10.1016/j.cmet.2023.07.006_bib186) 2022; 28
(10.1016/j.cmet.2023.07.006_bib143) 2014
(10.1016/j.cmet.2023.07.006_bib138) 2006
Ashton (10.1016/j.cmet.2023.07.006_bib39) 2018; 24
Lv (10.1016/j.cmet.2023.07.006_bib60) 2021; 33
Chini (10.1016/j.cmet.2023.07.006_bib59) 2021; 33
Clavell (10.1016/j.cmet.2023.07.006_bib169) 1986; 315
Andrzejewski (10.1016/j.cmet.2023.07.006_bib188) 2017; 26
Miwa (10.1016/j.cmet.2023.07.006_bib18) 1998; 34
Perez (10.1016/j.cmet.2023.07.006_bib171) 2017; 35
Hezaveh (10.101
References_xml – volume: 21
  start-page: 485
  year: 1958
  ident: 10.1016/j.cmet.2023.07.006_bib10
  article-title: Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose
  publication-title: J. Natl. Cancer Inst.
– volume: 185
  start-page: 2678
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib209
  article-title: Metabolic analysis as a driver for discovery, diagnosis, and therapy
  publication-title: Cell
  doi: 10.1016/j.cell.2022.06.029
– volume: 27
  start-page: 2184
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib145
  article-title: Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw410
– volume: 50
  start-page: 4417
  year: 1990
  ident: 10.1016/j.cmet.2023.07.006_bib19
  article-title: Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)
  publication-title: Cancer Res.
– volume: 108
  start-page: 987
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib165
  article-title: ERGO2: a prospective, randomized trial of calorie-restricted ketogenic diet and fasting in addition to reirradiation for malignant glioma
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2020.06.021
– volume: 11
  start-page: 87
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib15
  article-title: A systematic analysis of FDA-approved anticancer drugs
  publication-title: BMC Syst. Biol.
  doi: 10.1186/s12918-017-0464-7
– volume: 43
  start-page: 5601
  year: 1983
  ident: 10.1016/j.cmet.2023.07.006_bib155
  article-title: Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia
  publication-title: Cancer Res.
– volume: 327
  start-page: 1963
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib144
  article-title: Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 Randomized Clinical Trial
  publication-title: JAMA
  doi: 10.1001/jama.2022.6147
– volume: 22
  start-page: 452
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib13
  article-title: Developing dietary interventions as therapy for cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-022-00485-y
– volume: 216
  start-page: 768
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib177
  article-title: Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2022.07.123
– volume: 149
  start-page: 1060
  year: 2012
  ident: 10.1016/j.cmet.2023.07.006_bib47
  article-title: Ferroptosis: an iron-dependent form of nonapoptotic cell death
  publication-title: Cell
  doi: 10.1016/j.cell.2012.03.042
– volume: 24
  start-page: 1574
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib12
  article-title: Metabolic communication in the tumour-immune microenvironment
  publication-title: Nat. Cell Biol.
  doi: 10.1038/s41556-022-01002-x
– volume: 21
  start-page: 796
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib151
  article-title: Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30157-1
– volume: 12
  start-page: 31
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib1
  article-title: Hallmarks of cancer: new dimensions
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-21-1059
– volume: 8
  start-page: 1411
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib140
  article-title: Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA Randomized Clinical Trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2022.3511
– volume: 35
  start-page: 487
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib44
  article-title: NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2023.01.012
– volume: 55
  start-page: 324
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib79
  article-title: Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.01.006
– volume: 9
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib104
  article-title: Cytotoxic T-cells mediate exercise-induced reductions in tumor growth
  publication-title: eLife
  doi: 10.7554/eLife.59996
– volume: 36
  start-page: 2131
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib129
  article-title: Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance
  publication-title: Oncogene
  doi: 10.1038/onc.2016.370
– volume: 28
  start-page: 1860
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib95
  article-title: p63 and SOX2 dictate glucose reliance and metabolic vulnerabilities in squamous cell carcinomas
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2019.07.027
– volume: 59
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib107
  article-title: Impact of cancer metabolism on therapy resistance - clinical implications
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2021.100797
– volume: 115
  start-page: E11874
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib202
  article-title: Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1807305115
– volume: 144
  start-page: 93
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib122
  article-title: Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
  publication-title: J. Neurochem.
  doi: 10.1111/jnc.14250
– volume: 614
  start-page: 349
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib217
  article-title: Slow TCA flux and ATP production in primary solid tumours but not metastases
  publication-title: Nature
  doi: 10.1038/s41586-022-05661-6
– volume: 37
  start-page: 767
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib100
  article-title: Dietary approaches to cancer therapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.04.005
– volume: 118
  start-page: 99
  year: 1963
  ident: 10.1016/j.cmet.2023.07.006_bib167
  article-title: Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.118.1.99
– volume: 21
  start-page: 527
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib159
  article-title: Phase II Study of arginine deprivation therapy with pegargiminase in patients with relapsed sensitive or refractory small-cell lung cancer
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2020.07.012
– volume: 40
  start-page: 201
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib75
  article-title: Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.001
– volume: 25
  start-page: 968
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib197
  article-title: Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-019-0458-7
– volume: 5
  start-page: 47
  year: 2012
  ident: 10.1016/j.cmet.2023.07.006_bib173
  article-title: Role of glutamine in protection of intestinal epithelial tight junctions
  publication-title: J. Epithel. Biol. Pharmacol.
  doi: 10.2174/1875044301205010047
– volume: 42
  start-page: 419
  year: 2015
  ident: 10.1016/j.cmet.2023.07.006_bib77
  article-title: Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization
  publication-title: Immunity
  doi: 10.1016/j.immuni.2015.02.005
– volume: 81
  start-page: 5491
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib67
  article-title: PDSS1-mediated activation of CAMK2A-STAT3 signaling promotes metastasis in triple-negative breast cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-21-0747
– volume: 130
  start-page: 3865
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib132
  article-title: Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI131859
– volume: 583
  start-page: 620
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib91
  article-title: Fasting-mimicking diet and hormone therapy induce breast cancer regression
  publication-title: Nature
  doi: 10.1038/s41586-020-2502-7
– volume: 22
  start-page: 381
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib45
  article-title: Targeting ferroptosis as a vulnerability in cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-022-00459-0
– volume: 41
  start-page: 421
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib71
  article-title: Metabolic programming and immune suppression in the tumor microenvironment
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2023.01.009
– volume: 13
  start-page: 791
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib68
  article-title: Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28452-z
– volume: 7
  start-page: 62
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib168
  article-title: L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
  publication-title: J. Pharmacol. Pharmacother.
  doi: 10.4103/0976-500X.184769
– volume: 6
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib99
  article-title: Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.145207
– volume: 1
  start-page: 404
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib53
  article-title: NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism
  publication-title: Nat. Metab.
  doi: 10.1038/s42255-019-0043-x
– volume: 13
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib163
  article-title: A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abj5070
– volume: 544
  start-page: 372
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib103
  article-title: Modulating the therapeutic response of tumours to dietary serine and glycine starvation
  publication-title: Nature
  doi: 10.1038/nature22056
– volume: 10
  start-page: 1797
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib187
  article-title: Targeting metabolic plasticity and flexibility dynamics for cancer therapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-0844
– volume: 99
  start-page: 1986
  year: 2002
  ident: 10.1016/j.cmet.2023.07.006_bib156
  article-title: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
  publication-title: Blood
  doi: 10.1182/blood.V99.6.1986
– volume: 30
  start-page: 434
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib5
  article-title: Mechanisms and implications of metabolic heterogeneity in cancer
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2019.08.013
– volume: 20
  start-page: 274
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib21
  article-title: Leflunomide suppresses the growth of LKB1-inactivated tumors in the immune-competent host and attenuates distant cancer metastasis
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0567
– volume: 122
  start-page: 30
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib170
  article-title: The therapeutic potential of targeting tryptophan catabolism in cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-019-0664-6
– volume: 122
  start-page: 1837
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib33
  article-title: Stearoyl-CoA-desaturase-1 regulates gastric cancer stem-like properties and promotes tumour metastasis via Hippo/YAP pathway
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-020-0827-5
– volume: 18
  start-page: 2273
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib109
  article-title: Elevated hexokinase II expression confers acquired resistance to 4-hydroxytamoxifen in breast cancer cells
  publication-title: Mol. Cell. Proteomics
  doi: 10.1074/mcp.RA119.001576
– volume: 531
  start-page: 651
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib73
  article-title: Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism
  publication-title: Nature
  doi: 10.1038/nature17412
– volume: 39
  start-page: 3001
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib142
  article-title: First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2021.39.15_suppl.3001
– volume: 21
  start-page: 141
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib8
  article-title: Targeting cancer metabolism in the era of precision oncology
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-021-00339-6
– volume: 19
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib115
  article-title: Perturbing the dynamics and organization of cell membrane components: a new paradigm for cancer-targeted therapies
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19123871
– volume: 11
  start-page: 2261
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib176
  article-title: Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201600276
– volume: 82
  start-page: 665
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib220
  article-title: Integrated Metabolic profiling and transcriptional analysis reveals therapeutic modalities for targeting rapidly proliferating breast cancers
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-21-2745
– year: 2014
  ident: 10.1016/j.cmet.2023.07.006_bib143
– volume: 34
  start-page: 1843
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib78
  article-title: Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2022.08.016
– volume: 71
  start-page: 921
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib90
  article-title: Fasting-mimicking diet a clarion call for human nutrition research or an additional swan song for a commercial diet?
  publication-title: Int. J. Food Sci. Nutr.
  doi: 10.1080/09637486.2020.1746959
– volume: 13
  start-page: 4981
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib105
  article-title: Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-32521-8
– volume: 2
  start-page: 736
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib218
  article-title: Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer
  publication-title: Med (N Y)
– volume: 46
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib130
  article-title: The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer
  publication-title: Redox Biol.
  doi: 10.1016/j.redox.2021.102076
– volume: 40
  start-page: 639
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib184
  article-title: Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.05.009
– volume: 10
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib61
  article-title: Current use of asparaginase in acute lymphoblastic leukemia/lymphoblastic lymphoma
  publication-title: Front. Pediatr.
  doi: 10.3389/fped.2022.902117
– volume: 35
  start-page: 3003
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib171
  article-title: Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.15_suppl.3003
– volume: 22
  start-page: 280
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib43
  article-title: The role of ROS in tumour development and progression
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-021-00435-0
– year: 2005
  ident: 10.1016/j.cmet.2023.07.006_bib149
– volume: 10
  start-page: 372
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib194
  article-title: Hallmarks of resistance to immune-checkpoint inhibitors
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-20-0586
– volume: 3
  year: 2014
  ident: 10.1016/j.cmet.2023.07.006_bib41
  article-title: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
  publication-title: eLife
  doi: 10.7554/eLife.02242
– volume: 29
  start-page: 2299
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib86
  article-title: Energy and caloric restriction, and fasting and cancer: a narrative review
  publication-title: Support. Care Cancer
  doi: 10.1007/s00520-020-05879-y
– volume: 155
  start-page: 799
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib57
  article-title: Selective cytotoxicity of the NAMPT inhibitor FK866 toward gastric cancer cells with markers of the epithelial-mesenchymal transition, due to loss of NAPRT
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.05.024
– year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib160
– volume: 9
  start-page: 1201
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib117
  article-title: CPT1A/2-mediated FAO enhancement-a metabolic target in radioresistant breast cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.01201
– volume: 9
  start-page: 212
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib137
  article-title: Fasting and fasting mimicking diets in cancer prevention and therapy
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2022.12.006
– volume: 41
  start-page: 173
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib161
  article-title: Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2023.41.6_suppl.173
– volume: 129
  start-page: 71
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib172
  article-title: Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
  publication-title: Cancer
  doi: 10.1002/cncr.34512
– volume: 28
  start-page: 2865
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib186
  article-title: Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-4383
– volume: 183
  start-page: 1202
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib83
  article-title: Neurons release serine to support mRNA translation in pancreatic cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.016
– volume: 368
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib6
  article-title: Metabolic reprogramming and cancer progression
  publication-title: Science
  doi: 10.1126/science.aaw5473
– volume: 19
  start-page: 2502
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib22
  article-title: Selective vulnerability to pyrimidine starvation in hematologic malignancies revealed by AG-636, a novel clinical-stage inhibitor of dihydroorotate dehydrogenase
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0550
– volume: 2
  start-page: 414
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib34
  article-title: Fatty acid synthesis is required for breast cancer brain metastasis
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00183-y
– volume: 572
  start-page: 397
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib101
  article-title: Dietary methionine influences therapy in mouse cancer models and alters human metabolism
  publication-title: Nature
  doi: 10.1038/s41586-019-1437-3
– volume: 40
  start-page: 720
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib106
  article-title: Exercise-induced engagement of the IL-15/IL-15Ralpha axis promotes anti-tumor immunity in pancreatic cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.05.006
– volume: 34
  start-page: 1274
  year: 1998
  ident: 10.1016/j.cmet.2023.07.006_bib18
  article-title: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
  publication-title: Eur. J. Cancer
  doi: 10.1016/S0959-8049(98)00058-6
– volume: 2
  start-page: 132
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib63
  article-title: Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
  publication-title: Nat. Metab.
  doi: 10.1038/s42255-020-0174-0
– volume: 33
  start-page: 1076
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib59
  article-title: Evolving concepts in NAD(+) metabolism
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2021.04.003
– volume: 11
  start-page: 586
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib133
  article-title: HIF-1alpha regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-02768-4
– volume: 186
  start-page: 1670
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib11
  article-title: What is cancer metabolism?
  publication-title: Cell
  doi: 10.1016/j.cell.2023.01.038
– volume: 7
  start-page: 682
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib119
  article-title: Metabolic reprogramming in anticancer drug resistance: a focus on amino acids
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2021.02.004
– volume: 141
  start-page: 156
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib154
  article-title: Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
  publication-title: Blood
  doi: 10.1182/blood.2021014901
– volume: 15
  start-page: 3189
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib146
  article-title: A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas
  publication-title: Future Oncol.
  doi: 10.2217/fon-2019-0209
– volume: 70
  start-page: 8117
  year: 2010
  ident: 10.1016/j.cmet.2023.07.006_bib113
  article-title: De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-3871
– volume: 33
  start-page: 51
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib180
  article-title: Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2020.10.012
– volume: 315
  start-page: 657
  year: 1986
  ident: 10.1016/j.cmet.2023.07.006_bib169
  article-title: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198609113151101
– volume: 34
  start-page: 1151
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib190
  article-title: GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2022.06.010
– volume: 7
  start-page: 790
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib35
  article-title: Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2021.04.003
– volume: 34
  start-page: 581
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib196
  article-title: The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2022.02.010
– volume: 34
  start-page: 90
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib221
  article-title: Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2021.12.001
– volume: 9
  start-page: 509
  year: 1989
  ident: 10.1016/j.cmet.2023.07.006_bib16
  article-title: Nobel Lecture. The purine path to chemotherapy
  publication-title: Biosci. Rep.
  doi: 10.1007/BF01119794
– volume: 3
  start-page: 330
  year: 2003
  ident: 10.1016/j.cmet.2023.07.006_bib17
  article-title: 5-fluorouracil: mechanisms of action and clinical strategies
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1074
– volume: 4
  start-page: 124ra27
  year: 2012
  ident: 10.1016/j.cmet.2023.07.006_bib92
  article-title: Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3003293
– volume: 35
  start-page: 633
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib74
  article-title: Linoleic acid potentiates CD8(+) T cell metabolic fitness and antitumor immunity
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2023.02.013
– volume: 116
  start-page: 631
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib118
  article-title: Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1808834116
– volume: 22
  start-page: 467
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib65
  article-title: Polyamines in cancer: integrating organismal metabolism and antitumour immunity
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-022-00473-2
– volume: 18
  start-page: 379
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib64
  article-title: Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-019-0016-5
– volume: 34
  start-page: 355
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib4
  article-title: The hallmarks of cancer metabolism: still emerging
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2022.01.007
– volume: 582
  start-page: 586
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib126
  article-title: Oncometabolites suppress DNA repair by disrupting local chromatin signalling
  publication-title: Nature
  doi: 10.1038/s41586-020-2363-0
– volume: 28
  start-page: 3248
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib139
  article-title: Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-22-0061
– volume: 10
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib208
  article-title: Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination
  publication-title: Adv. Sci.
– volume: 27
  start-page: 136
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib116
  article-title: JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2017.11.001
– volume: 13
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib56
  article-title: Review of various NAMPT inhibitors for the treatment of cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.970553
– volume: 12
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib20
  article-title: Inhibitors of the cancer target ribonucleotide reductase, past and present
  publication-title: Biomolecules
  doi: 10.3390/biom12060815
– volume: 167
  start-page: 829
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib72
  article-title: L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity
  publication-title: Cell
  doi: 10.1016/j.cell.2016.09.031
– volume: 1
  start-page: 345
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib27
  article-title: alpha-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-020-0035-5
– volume: 41
  start-page: 304
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib222
  article-title: Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.12.008
– volume: 40
  start-page: 957
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib24
  article-title: A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.07.012
– volume: 175
  start-page: 39
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib123
  article-title: S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-019-05146-7
– volume: 458
  start-page: 725
  year: 2009
  ident: 10.1016/j.cmet.2023.07.006_bib89
  article-title: Tumours with PI3K activation are resistant to dietary restriction
  publication-title: Nature
  doi: 10.1038/nature07782
– volume: 49
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib114
  article-title: Phospholipids and cholesterol: inducers of cancer multidrug resistance and therapeutic targets
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2019.100670
– volume: 11
  start-page: 656
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib174
  article-title: Recent advances in NAMPT inhibitors: a novel immunotherapic strategy
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.00656
– volume: 35
  start-page: 2919
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib164
  article-title: Low-Fat dietary pattern and breast cancer mortality in the Women's Health Initiative randomized controlled trial
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.72.0326
– volume: 103
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib37
  article-title: Clinical development of IDH1 inhibitors for cancer therapy
  publication-title: Cancer Treat Rev.
  doi: 10.1016/j.ctrv.2021.102334
– volume: 98
  start-page: 1431
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib134
  article-title: The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells
  publication-title: J. Mol. Med.
  doi: 10.1007/s00109-020-01959-y
– volume: 81
  start-page: 2289
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib51
  article-title: Targeting mitochondrial iron metabolism suppresses tumor growth and metastasis by inducing mitochondrial dysfunction and mitophagy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-1628
– volume: 7
  start-page: 1669
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib152
  article-title: Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2021.3836
– volume: 8
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib181
  article-title: Identification and characterization of robust hepatocellular carcinoma prognostic subtypes based on an integrative metabolite-protein interaction network
  publication-title: Adv. Sci.
  doi: 10.1002/advs.202100311
– volume: 21
  start-page: 498
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib111
  article-title: Extracellular vesicle-packaged HIF-1alpha-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells
  publication-title: Nat. Cell Biol.
  doi: 10.1038/s41556-019-0299-0
– volume: 10
  start-page: 201
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib85
  article-title: Roles and molecular mechanisms of physical exercise in cancer prevention and treatment
  publication-title: J. Sport Health Sci.
  doi: 10.1016/j.jshs.2020.07.008
– volume: 23
  start-page: 234
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib108
  article-title: Glycolysis-induced drug resistance in tumors-a response to danger signals?
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2020.12.009
– volume: 612
  start-page: 338
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib175
  article-title: Ferroptosis of tumour neutrophils causes immune suppression in cancer
  publication-title: Nature
  doi: 10.1038/s41586-022-05443-0
– volume: 29
  start-page: 115
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib40
  article-title: Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-02103-8
– volume: 238
  start-page: 787
  year: 1948
  ident: 10.1016/j.cmet.2023.07.006_bib7
  article-title: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM194806032382301
– volume: 605
  start-page: 747
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib189
  article-title: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis
  publication-title: Nature
  doi: 10.1038/s41586-022-04758-2
– volume: 4
  start-page: 693
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib81
  article-title: Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix
  publication-title: Nat. Metab.
  doi: 10.1038/s42255-022-00582-0
– volume: 81
  start-page: 2317
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib98
  article-title: Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2021.03.037
– volume: 24
  start-page: 230
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib124
  article-title: Cancer-cell-derived GABA promotes beta-catenin-mediated tumour growth and immunosuppression
  publication-title: Nat. Cell Biol.
  doi: 10.1038/s41556-021-00820-9
– volume: 29
  start-page: 1217
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib125
  article-title: Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2019.01.011
– volume: 124
  start-page: 269
  year: 1956
  ident: 10.1016/j.cmet.2023.07.006_bib3
  article-title: On respiratory impairment in cancer cells
  publication-title: Science
  doi: 10.1126/science.124.3215.269
– volume: 62
  start-page: 7976
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib62
  article-title: Intracellular trapping of the selective phosphoglycerate dehydrogenase (PHGDH) inhibitor BI-4924 disrupts serine biosynthesis
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.9b00718
– volume: 29
  start-page: 104
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib182
  article-title: An integrated metabolic atlas of clear cell renal cell carcinoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.12.004
– volume: 10
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib205
  article-title: Metabolomic profiling of rare cell populations isolated by flow cytometry from tissues
  publication-title: eLife
  doi: 10.7554/eLife.61980
– volume: 36
  start-page: 3223
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib157
  article-title: Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2018.78.9602
– volume: 27
  start-page: 242
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib48
  article-title: Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis
  publication-title: Cell Death Differ.
  doi: 10.1038/s41418-019-0352-3
– volume: 379
  start-page: 351
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib42
  article-title: Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides
  publication-title: Science
  doi: 10.1126/science.ade3332
– volume: 119
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib212
  article-title: Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 82
  start-page: 2215
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib46
  article-title: Ferroptosis at the intersection of lipid metabolism and cellular signaling
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2022.03.022
– volume: 23
  start-page: 275
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib14
  article-title: Nucleotide metabolism: a pan-cancer metabolic dependency
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-023-00557-7
– volume: 75
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib206
  article-title: Single-cell metabolomics: where are we and where are we going?
  publication-title: Curr. Opin. Biotechnol.
  doi: 10.1016/j.copbio.2022.102693
– volume: 29
  start-page: 1390
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib131
  article-title: Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2019.02.001
– volume: 605
  start-page: 160
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib97
  article-title: beta-Hydroxybutyrate suppresses colorectal cancer
  publication-title: Nature
  doi: 10.1038/s41586-022-04649-6
– volume: 20
  start-page: 1083
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib158
  article-title: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30274-8
– volume: 5
  start-page: 231
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib54
  article-title: NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00326-0
– volume: 98
  start-page: 565
  year: 1953
  ident: 10.1016/j.cmet.2023.07.006_bib166
  article-title: Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.98.6.565
– volume: 40
  start-page: 2491
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib84
  article-title: Exercise, diet, and weight management during cancer treatment: ASCO guideline
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.22.00687
– volume: 13
  start-page: 672
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib128
  article-title: Discovery of targets for immune-metabolic antitumor drugs identifies estrogen-related receptor alpha
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-22-0244
– volume: 28
  start-page: 245
  year: 2010
  ident: 10.1016/j.cmet.2023.07.006_bib201
  article-title: What is flux balance analysis?
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1614
– volume: 150
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib28
  article-title: Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.104511
– volume: 20
  start-page: 516
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib70
  article-title: Metabolism of immune cells in cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-0273-y
– volume: 31
  start-page: 487
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib127
  article-title: O(2)(⋅-) and H(2)O(2)-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.02.018
– volume: 11
  start-page: 3811
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib120
  article-title: Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17512-x
– volume: 184
  start-page: 5309
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib193
  article-title: Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
  publication-title: Cell
  doi: 10.1016/j.cell.2021.09.020
– volume: 21
  start-page: 529
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib195
  article-title: Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-022-00493-5
– volume: 11
  start-page: 4205
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib29
  article-title: GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18020-8
– volume: 26
  start-page: 842
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib32
  article-title: Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2017.09.018
– volume: 29
  start-page: 1237
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib121
  article-title: Redox paradox: a novel approach to therapeutics-resistant cancer
  publication-title: Antioxid. Redox Signal.
  doi: 10.1089/ars.2017.7485
– volume: 9
  start-page: 1025
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib49
  article-title: Salinomycin kills cancer stem cells by sequestering iron in lysosomes
  publication-title: Nat. Chem.
  doi: 10.1038/nchem.2778
– volume: 18
  start-page: 707
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib93
  article-title: Fasting and cancer: molecular mechanisms and clinical application
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-018-0061-0
– volume: 24
  start-page: 1202
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib58
  article-title: NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-2575
– volume: 33
  start-page: 499
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib82
  article-title: Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2021.01.018
– volume: 55
  start-page: 1748
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib80
  article-title: Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.07.017
– volume: 9
  start-page: 216
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib36
  article-title: The emerging role and targetability of the TCA cycle in cancer metabolism
  publication-title: Protein Cell
  doi: 10.1007/s13238-017-0451-1
– volume: 20
  start-page: 28
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib76
  article-title: The cancer metabolic reprogramming and immune response
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01316-8
– volume: 114
  start-page: 1305
  year: 2016
  ident: 10.1016/j.cmet.2023.07.006_bib26
  article-title: Hallmarks of cancer stem cell metabolism
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2016.152
– volume: 493
  start-page: 542
  year: 2013
  ident: 10.1016/j.cmet.2023.07.006_bib102
  article-title: Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
  publication-title: Nature
  doi: 10.1038/nature11743
– year: 2001
  ident: 10.1016/j.cmet.2023.07.006_bib147
– volume: 40
  start-page: 939
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib23
  article-title: De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.07.011
– volume: 365
  start-page: 576
  year: 2011
  ident: 10.1016/j.cmet.2023.07.006_bib52
  article-title: Deferoxamine for advanced hepatocellular carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc1105726
– volume: 35
  start-page: 517
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib204
  article-title: PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2023.01.010
– volume: 13
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib136
  article-title: Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abc8188
– volume: 29
  start-page: 156
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib183
  article-title: PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2018.09.002
– volume: 32
  start-page: 1063
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib207
  article-title: SCENITH: A flow cytometry-based method to functionally profile energy metabolism with single-cell resolution
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2020.11.007
– volume: 14
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib213
  article-title: Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abk2756
– volume: 52
  start-page: 17
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib191
  article-title: Top 10 challenges in cancer immunotherapy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.12.011
– volume: 20
  start-page: 353
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib214
  article-title: Identification of bioactive metabolites using activity metabolomics
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-019-0108-4
– volume: 5
  start-page: S21
  issue: Suppl 1
  year: 2009
  ident: 10.1016/j.cmet.2023.07.006_bib9
  article-title: Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects
  publication-title: J. Cancer Res. Ther.
  doi: 10.4103/0973-1482.55136
– volume: 10
  year: 2015
  ident: 10.1016/j.cmet.2023.07.006_bib162
  article-title: A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0127246
– year: 2006
  ident: 10.1016/j.cmet.2023.07.006_bib138
– volume: 34
  start-page: 186
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib38
  article-title: Biological role and therapeutic potential of IDH mutations in cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.04.011
– volume: 25
  start-page: 850
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib198
  article-title: The landscape of cancer cell line metabolism
  publication-title: Nat. Med.
  doi: 10.1038/s41591-019-0404-8
– volume: 593
  start-page: 282
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib178
  article-title: Cell-programmed nutrient partitioning in the tumour microenvironment
  publication-title: Nature
  doi: 10.1038/s41586-021-03442-1
– volume: 21
  start-page: 753
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib112
  article-title: Tumour fatty acid metabolism in the context of therapy resistance and obesity
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-021-00388-4
– year: 2003
  ident: 10.1016/j.cmet.2023.07.006_bib148
– volume: 378
  start-page: 2386
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib150
  article-title: Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1716984
– volume: 11
  start-page: 838
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib192
  article-title: The next decade of immune checkpoint therapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-1680
– volume: 33
  start-page: 110
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib60
  article-title: NAD(+) metabolism maintains inducible PD-L1 expression to drive tumor immune evasion
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2020.10.021
– volume: 151
  start-page: 16
  year: 2015
  ident: 10.1016/j.cmet.2023.07.006_bib55
  article-title: Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2015.02.004
– volume: 24
  start-page: 2482
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib39
  article-title: Oxidative phosphorylation as an emerging target in cancer therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3070
– volume: 12
  start-page: 6201
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib88
  article-title: Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-26431-4
– volume: 13
  start-page: 496
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib200
  article-title: Dysregulated Lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-21-0218
– volume: 126
  start-page: 1925
  year: 2015
  ident: 10.1016/j.cmet.2023.07.006_bib30
  article-title: Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias
  publication-title: Blood
  doi: 10.1182/blood-2014-12-617498
– volume: 33
  start-page: 1111
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib66
  article-title: Creatine promotes cancer metastasis through activation of Smad2/3
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2021.03.009
– volume: 4
  start-page: 1119
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib199
  article-title: Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer
  publication-title: Nat. Metab.
  doi: 10.1038/s42255-022-00636-3
– volume: 116
  start-page: 52
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib185
  article-title: Spatially resolved metabolomics to discover tumor-associated metabolic alterations
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1808950116
– volume: 35
  start-page: 212
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib216
  article-title: Q-Flux: a method to assess hepatic mitochondrial succinate dehydrogenase, methylmalonyl-CoA mutase, and glutaminase fluxes in vivo
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2022.11.011
– volume: 560
  start-page: 499
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib96
  article-title: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
  publication-title: Nature
  doi: 10.1038/s41586-018-0343-4
– volume: 23
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib135
  article-title: Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
  publication-title: Obes. Rev.
  doi: 10.1111/obr.13358
– volume: 10
  start-page: e46
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib153
  article-title: Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
  publication-title: Lancet. Haematol.
  doi: 10.1016/S2352-3026(22)00292-7
– volume: 26
  start-page: 778
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib188
  article-title: PGC-1alpha promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2017.09.006
– volume: 7
  start-page: 11
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib94
  article-title: Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00831-w
– volume: 8
  start-page: 44171
  year: 2017
  ident: 10.1016/j.cmet.2023.07.006_bib110
  article-title: Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17396
– volume: 173
  start-page: 822
  year: 2018
  ident: 10.1016/j.cmet.2023.07.006_bib210
  article-title: Metabolomics and isotope tracing
  publication-title: Cell
  doi: 10.1016/j.cell.2018.03.055
– volume: 10
  start-page: 721
  year: 2014
  ident: 10.1016/j.cmet.2023.07.006_bib203
  article-title: Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling
  publication-title: Mol. Syst. Biol.
  doi: 10.1002/msb.145122
– volume: 40
  start-page: 365
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib179
  article-title: CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.02.003
– volume: 13
  start-page: 2176
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib50
  article-title: Targeted co-delivery of the iron chelator deferoxamine and a HIF1alpha inhibitor impairs pancreatic tumor growth
  publication-title: ACS Nano
– volume: 35
  start-page: 84
  year: 2023
  ident: 10.1016/j.cmet.2023.07.006_bib219
  article-title: Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2022.09.021
– volume: 79
  start-page: P6-20
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib141
  article-title: Abstract P6-20-07: efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.SABCS18-P6-20-07
– volume: 32
  start-page: 477
  year: 2022
  ident: 10.1016/j.cmet.2023.07.006_bib69
  article-title: Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
  publication-title: Cell Res.
  doi: 10.1038/s41422-022-00614-0
– volume: 18
  start-page: 747
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib211
  article-title: Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices
  publication-title: Nat. Methods
  doi: 10.1038/s41592-021-01197-1
– volume: 368
  start-page: 283
  year: 2020
  ident: 10.1016/j.cmet.2023.07.006_bib215
  article-title: Metabolomics and mass spectrometry imaging reveal channeled de novo purine synthesis in cells
  publication-title: Science
  doi: 10.1126/science.aaz6465
– volume: 11
  start-page: 1052
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib25
  article-title: Mitochondrial and metabolic pathways regulate nuclear gene expression to control differentiation, stem cell function, and immune response in leukemia
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-1227
– volume: 38
  start-page: 401
  year: 2019
  ident: 10.1016/j.cmet.2023.07.006_bib31
  article-title: ACLY facilitates colon cancer cell metastasis by CTNNB1
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-019-1391-9
– volume: 11
  start-page: 325
  year: 2011
  ident: 10.1016/j.cmet.2023.07.006_bib2
  article-title: Otto Warburg's contributions to current concepts of cancer metabolism
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3038
– volume: 599
  start-page: 302
  year: 2021
  ident: 10.1016/j.cmet.2023.07.006_bib87
  article-title: Low glycaemic diets alter lipid metabolism to influence tumour growth
  publication-title: Nature
  doi: 10.1038/s41586-021-04049-2
SSID ssj0036393
Score 2.6663373
SecondaryResourceType review_article
Snippet Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1283
SubjectTerms Humans
Metabolic Networks and Pathways
Neoplasms - metabolism
Title Emerging therapies in cancer metabolism
URI https://www.ncbi.nlm.nih.gov/pubmed/37557070
https://www.proquest.com/docview/2848842424
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ra9swEBZbRmEvZd3aLu1aPBjsoTjIsizLj9vYCIHuYSTgPRlZVotLcUsWP7S_vneS7TghKc1eRFAc2dKn3J3Od98R8iWHP1DBYuHLggsf2V_8XERYzIwHWvCEFZbx5vK3GM_4JI3SZWU6m12yyEf6cWNeyf-gCn2AK2bJ7oBsNyh0wGfAF1pAGNoXYYwepesm32mu7ksbXIVxXNrMsTY0AHzbUgS2bAToq1v7CtY7LZX1mf4tOzFQOyhV5U96Wyit3WWNwkMTuKmK8qcu-y4EFtoAthWpF1EftFnQF4uORaSBX_ZkHGi0sKcvUQlulMXOLXAz0jCpEd7WsqTSDcTXawqpCxNsI9BuMhwjwzEyiu_LxWvyhsG5wGZspt9b1RuCuWUzKtr5NFlSLqBv_TlWLZEtxwtrZkzfkf3mfOB9c2AfkFemek_2XMXQhw_kawu510HulZXnIPeWuB6S2a-f0x9jv6l14euQxws_V5oVIjcioZESXBbyShqV0NAoXnDNYw0NN8JEMRWMm0AwBr30Kk800yYIj8iguqvMR-IFQoaKSc0TZbiQLClkYWhEuaJCBbkYkqCdd6YbInisR3KbbV_vIbnofnPvaFCevfpzu5wZSCt8BaUqc1f_y8AYkpJjStKQHLt17sYLY6SDi-nJTvc6JW-XW_oTGSzmtTkDO3GRn9u98QQYSWHc
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emerging+therapies+in+cancer+metabolism&rft.jtitle=Cell+metabolism&rft.au=Xiao%2C+Yi&rft.au=Yu%2C+Tian-Jian&rft.au=Xu%2C+Ying&rft.au=Ding%2C+Rui&rft.date=2023-08-08&rft.issn=1550-4131&rft.volume=35&rft.issue=8&rft.spage=1283&rft.epage=1303&rft_id=info:doi/10.1016%2Fj.cmet.2023.07.006&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_cmet_2023_07_006
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1550-4131&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1550-4131&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1550-4131&client=summon